A Global Retrospective and Physician-Based Analysis of Adherence to Tyrosine Kinase Inhibitor (TKI) Therapies for Chronic Myeloid Leukemia (CML)

François Guilhot¹, John Coombs¹, Oleg Zernovak¹, Tomasz Szczudlo² and Gianantonio Rosti³

¹Clinical Investigation Centre P 802 INSERM, CHU de Poitiers, Poitiers, France; ²Novartis Pharmaceuticals Corporation, East Hanover, NJ; ³Department of Hematology/Oncology, “L. and A. Seraglio”, St Orsola University Hospital, Bologna, Italy

INTRODUCTION

• Tyrosine kinase inhibitors (TKIs) have proven to be highly effective in the treatment of various phases of CML.
• Several studies have demonstrated that adherence to TKI therapy is a predictor of achieving optimal outcomes.*
• Meisel and colleagues reported a strong correlation between adherence rates (90% or 95%) and the 6-year probability of a major molecular response (MMR; 3% vs. 63.6%; P = .001) and complete molecular response (CMR; 5% vs. 94.5%; P = .001).

OBJECTIVE

• To establish the key determinants of drug adherence, and to retain a type of adherence rate to be used as a baseline for future comparison.

METHODS

• 455 CML-treating physicians from 5 countries participated in an online quantitative survey and provided patient treatment histories.
• Physicians were asked to rate statements on a scale of 1 (Always) to 7 (Never) in full agreement.
• 1,155 patient treatment histories and compliance records were retrospectively analyzed.

RESULTS

Figure 1: Percentage of Patient Treatment Based on the Use of Therapy

Figure 4: Physician Attitudes Towards Patient Adherence

Figure 7: Adherence Support Novartis Healthcare Providers Currently Offer to Help Physicians Believe That They Should Play*

Figure 8: Physician Monitoring of non-adherence*

Figure 9: Physician monitoring of non-adherence*

CONCLUSIONS

• Only 42%-63% of patients were fully adherent to therapy across all 5 countries that participated in the study.
• Overall, >10% of patients missed ≥ 10% of their prescribed daily doses.

DISCLOSURES

• Meisel and colleagues: speaker, consultant, fee for service, honoraria
• Guilhot: consultant, honoraria, membership on advisory boards

ACKNOWLEDGMENT

The authors would like to thank Marc Paolantonio of Novartis for his support with these data.

* Includes responses from physicians in France, Italy, and Spain.